Eye Injections of Bevacizumab for Lowering Risk of Scar Tissue in the Retina and Repeated Retinal Detachment.

• Status: Completed
• Trial end date: 2014-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to examine the effects of a drug called bevacizumab (Avastin) on the rates of recurrent retinal detachment and scar tissue formation.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wills Eye
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• Ability to provide written informed consent and comply with study assessments for the full duration of the study

• Undergoing pars plana vitrectomy with or without scleral buckling for recurrent RD due to PVR with planned silicone oil instillation.

Exclusion Criteria:

• Prior anti-VEGF (vascular endothelial growth factor) injections within 3 months of retinal detachment surgery.

• Traction retinal detachment due to proliferative diabetic retinopathy.

• Inability to flatten retina completely intraoperatively

• Known allergy or contraindication to intravitreal bevacizumab